PROTHENA CORPORATION PUBLIC LIMITED COMPANY Increase Decrease In Operating Lease Liability
PROTHENA CORPORATION PUBLIC LIMITED COMPANY (PRTA) reported Increase Decrease In Operating Lease Liability of -$1.45 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOperatingLeaseLiability · last filed 2026-08-06
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for the quarter ending 2026-06-30 was -$727.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for the quarter ending 2026-03-31 was -$719.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for the quarter ending 2025-12-31 was -$709.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for the quarter ending 2025-09-30 was -$699.00K.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for fiscal 2025 was -$2.69M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for fiscal 2024 was -$2.24M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for fiscal 2023 was -$6.36M.
- PROTHENA CORPORATION PUBLIC LIMITED COMPANY increase decrease in operating lease liability for fiscal 2022 was -$6.00M.
| Period end | Increase Decrease In Operating Lease Liability 3 month | Increase Decrease In Operating Lease Liability 6 month | Increase Decrease In Operating Lease Liability 9 month | Increase Decrease In Operating Lease Liability 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$727.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.45M 10-Q · filed 2026-08-06 | -$2.15M derived: sum of 3 quarters · filed 2026-08-06 | -$2.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$719.00K 10-Q · filed 2026-05-07 | -$1.43M derived: sum of 2 quarters · filed 2026-05-07 | -$2.13M derived: sum of 3 quarters · filed 2026-05-07 | -$2.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$709.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$1.41M derived: sum of 2 quarters · filed 2026-02-27 | -$2.05M derived: sum of 3 quarters · filed 2026-08-06 | -$2.69M 10-K · filed 2026-02-27 |
| 2025-09-30 | -$699.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.34M derived: sum of 2 quarters · filed 2026-08-06 | -$1.99M 10-Q · filed 2025-11-06 | -$2.64M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$641.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.29M 10-Q · filed 2026-08-06 | -$1.94M derived: sum of 3 quarters · filed 2026-08-06 | -$2.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$645.00K 10-Q · filed 2026-05-07 | -$1.30M derived: sum of 2 quarters · filed 2026-05-07 | -$1.92M derived: sum of 3 quarters · filed 2026-05-07 | -$2.52M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$651.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$1.27M derived: sum of 2 quarters · filed 2026-02-27 | -$1.87M derived: sum of 3 quarters · filed 2026-02-27 | -$2.24M 10-K · filed 2026-02-27 |
| 2024-09-30 | -$623.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -$1.22M derived: sum of 2 quarters · filed 2025-11-06 | -$1.58M 10-Q · filed 2025-11-06 | -$3.13M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-06-30 | -$597.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$962.00K 10-Q · filed 2025-08-04 | -$2.51M derived: sum of 3 quarters · filed 2026-02-27 | -$4.13M derived: sum of 4 quarters · filed 2026-02-27 |
| 2024-03-31 | -$365.00K 10-Q · filed 2025-05-08 | -$1.91M derived: sum of 2 quarters · filed 2026-02-27 | -$3.53M derived: sum of 3 quarters · filed 2026-02-27 | -$5.14M derived: sum of 4 quarters · filed 2026-02-27 |
| 2023-12-31 | -$1.55M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$3.17M derived: sum of 2 quarters · filed 2026-02-27 | -$4.77M derived: sum of 3 quarters · filed 2026-02-27 | -$6.36M 10-K · filed 2026-02-27 |
| 2023-09-30 | -$1.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$3.22M derived: sum of 2 quarters · filed 2024-11-12 | -$4.81M 10-Q · filed 2024-11-12 | -$6.37M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-06-30 | -$1.60M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$3.19M 10-Q · filed 2024-08-08 | -$4.75M derived: sum of 3 quarters · filed 2025-02-27 | -$6.30M derived: sum of 4 quarters · filed 2025-02-27 |
| 2023-03-31 | -$1.59M 10-Q · filed 2024-05-08 | -$3.15M derived: sum of 2 quarters · filed 2025-02-27 | -$4.69M derived: sum of 3 quarters · filed 2025-02-27 | -$6.15M derived: sum of 4 quarters · filed 2025-02-27 |
| 2022-12-31 | -$1.56M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | -$3.10M derived: sum of 2 quarters · filed 2025-02-27 | -$4.56M derived: sum of 3 quarters · filed 2025-02-27 | -$6.00M 10-K · filed 2025-02-27 |
| 2022-09-30 | -$1.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$3.00M derived: sum of 2 quarters · filed 2023-11-02 | -$4.44M 10-Q · filed 2023-11-02 | -$5.87M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | -$1.46M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$2.90M 10-Q · filed 2023-08-03 | -$4.33M derived: sum of 3 quarters · filed 2024-02-22 | -$5.72M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | -$1.44M 10-Q · filed 2023-05-04 | -$2.87M derived: sum of 2 quarters · filed 2024-02-22 | -$4.26M derived: sum of 3 quarters · filed 2024-02-22 | -$5.62M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | -$1.43M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | -$2.82M derived: sum of 2 quarters · filed 2024-02-22 | -$4.17M derived: sum of 3 quarters · filed 2024-02-22 | -$5.51M 10-K · filed 2024-02-22 |
| 2021-09-30 | -$1.40M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$2.75M derived: sum of 2 quarters · filed 2022-11-03 | -$4.08M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$1.35M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | -$2.69M 10-Q · filed 2022-08-08 | ||
| 2021-03-31 | -$1.34M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$5.10M 10-K · filed 2023-02-28 | |||
| 2019-12-31 | -$4.72M 10-K · filed 2022-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DiaMedica Therapeutics Inc. (DMAC) | United States | $0.423B | -10.11 |
| CYPHERPUNK TECHNOLOGIES INC. (CYPH) | United States | $0.438B | -75.63 |
| Atea Pharmaceuticals, Inc. (AVIR) | United States | $0.414B | -2.26 |
| ARS Pharmaceuticals, Inc. (SPRY) | United States | $0.414B | -3.70 |
| Quoin Pharmaceuticals Ltd. (QNRX) | $0.443B | -17.85 | |
| RELMADA THERAPEUTICS, INC. (RLMD) | United States | $0.406B | -11.92 |
| Opus Genetics, Inc. (IRD) | United States | $0.406B | -3.16 |
| Arcturus Therapeutics Holdings Inc. (ARCT) | $0.402B | -2.05 | |
| GALECTIN THERAPEUTICS INC (GALT) | United States | $0.399B | -11.06 |
| MapLight Therapeutics, Inc. (MPLT) | United States | $0.459B | -7.10 |